ArticleClinical and molecular hepatology2026

Reply to correspondence on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study".

Xingyu YaoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.